Sol-Gel Technologies Ltd. (SLGL)
NASDAQ: SLGL · IEX Real-Time Price · USD
0.501
+0.051 (11.33%)
At close: Jul 26, 2024, 4:00 PM
0.500
-0.001 (-0.20%)
After-hours: Jul 26, 2024, 7:01 PM EDT
Sol-Gel Technologies Revenue
Sol-Gel Technologies had revenue of $466.00K in the quarter ending March 31, 2024, a decrease of -38.52%. This brings the company's revenue in the last twelve months to $1.72M, down -62.92% year-over-year. In the year 2023, Sol-Gel Technologies had annual revenue of $1.55M, down -59.98%.
Revenue (ttm)
$1.72M
Revenue Growth
-62.92%
P/S Ratio
8.11
Revenue / Employee
$47,778
Employees
36
Market Cap
13.96M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.55M | -2.33M | -59.98% |
Dec 31, 2022 | 3.88M | -27.39M | -87.58% |
Dec 31, 2021 | 31.27M | 22.50M | 256.54% |
Dec 31, 2020 | 8.77M | -14.13M | -61.71% |
Dec 31, 2019 | 22.90M | 22.78M | 17,655.04% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSLGL News
- 11 days ago - Sol-Gel Technologies Announces Management Realignment - GlobeNewsWire
- 2 months ago - Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 2 months ago - Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel - GlobeNewsWire
- 4 months ago - Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream - GlobeNewsWire
- 4 months ago - Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments - GlobeNewsWire
- 8 months ago - Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study - GlobeNewsWire
- 8 months ago - Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610 - GlobeNewsWire
- 9 months ago - Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update - GlobeNewsWire